These results highlight CD24 as an innate immune checkpoint that can be therapeutically targeted to restore normal clearance of neutrophils and avoid pathogenic cell-cell interactions associated with high risk in MPN. This evidence concerns the gene CD24 and myeloproliferative disorder.